Not finding it? Sign in to also search OpenAlex live.
-
A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma2023 Drug Delivery and Translational Research article Medicine Multiple Myeloma Research and Treatments Open access
Josbert M. Metselaar, Twan Lammers, Amelie Boquoi, Roland R. Fenk, Fabio J. Testaquadra, Mirle Schemionek, +4 more
13citations -
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study2022 Journal of Crohn s and Colitis article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Edward V. Loftus, Severine A.R.A. Vermeire, Brian G. Feagan, Franck‐Olivier Le Brun, Alessandra Faria Oortwijn, Ulrik Moerch, +2 more
12citations -
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial
Anna Paula Brandt, Christoph Schultheiß, Konrad Friedrich Klinghammer, Philippe Schafhausen, Chia‐Jung Busch, Markus Blaurock, +8 more
11citations -
Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial)
Sai Ping Lau, Freek R. van ‘t Land, Sjoerd H. van der Burg, Marjolein Y.V. Homs, Martijn P. Lolkema, Joachim G.J.V. Aerts, +1 more
9citations -
Optimisation of Organ Preservation treatment strategies in patients with rectal cancer with a good clinical response after neoadjuvant (chemo)radiotherapy: Additional contact X-ray brachytherapy versus eXtending the observation period and local excision (OPAXX) — protocol for two multicentre, parallel, single-arm, phase II studies
Barbara M. Geubels, Baukelien van Triest, Femke P. Peters, Monique Maas, Geerard L. Beets, Corrie A.M. Marijnen, +7 more
9citations -
CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER.2023 Journal of Clinical Oncology conference-abstract Medicine Endometrial and Cervical Cancer Treatments Open access
Jessica Nell McAlpine, Kathy Chai-Zung Han, Mary A. Kinloch, Maroie Barkati, Sarah Elizabeth Ferguson, Anthony Fyles, +13 more
8citations -
POS-132 TRIAL DESIGN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NARSOPLIMAB SAFETY AND EFFICACY IN IGA NEPHROPATHY (ARTEMIS-IGAN)2022 Kidney International Reports conference-abstract Medicine Renal Diseases and Glomerulopathies Open access
Richard A. Lafayette, Brad H. Rovin, Jürgen Floege, Vladimı́r Tesař, Hengguo Zhang, Jonathan Barratt
8citations -
Onset of Adverse Abdominal Events Due to Intestinal Ischemia-Reperfusion Injury after Aortic Cross-Clamping Is Associated with Elevated HSP70 Serum Levels in the Early Postoperative Phase2022 International Journal of Molecular Sciences article Medicine Aortic Disease and Treatment Approaches Open access
Panagiotis Doukas, Gabriel Hellfritsch, Hanif Krabbe, Jelle Frankort, Michael Johan Jacobs, Alexander Gombert, +1 more
8citations -
The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.
Hans A. J. Gelderblom, Victoria E. H. Wang, Mark Doherty, Ana Sebio, Silvia Stacchiotti, Breelyn Ann Wilky, +14 more
7citations -
Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study2020 Blood article Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Vaishali Sanchorawala, Giovanni O. Palladini, Monique C. Minnema, Arnaud Jaccard, Hans Chulhee Lee, Simon DJ Gibbs, +28 more
7citations -
Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies2023 Journal of Crohn s and Colitis article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Severine A.R.A. Vermeire, Brian G. Feagan, Laurent Peyrin‐Biroulet, Alessandra Faria Oortwijn, Margaux Faes, Angela de Haas, +1 more
7citations -
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry2023 Journal of Thrombosis and Thrombolysis article Medicine Atrial Fibrillation Management and Outcomes Open access
Wern Yew Ding, Ameenathul M. Fawzy, Giulio Francesco Romiti, Marco Proietti, Daniele Pastori, Menno Volkert Huisman, +86 more
7citations -
Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study
Linda Dirven, Abigirl Machingura, Martin J. van den Bent, Corneel Coens, Andrew Bottomley, Alba Ariela Brandes, +7 more
7citations -
Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Andrew Tucker Kuykendall, Aniket Bankar, Kristen Marie Pettit, Joseph James Shatzel, Alessandro Lucchesi, Valentín García‐Gutiérrez, +20 more
6citations -
Heart failure in patients with recently diagnosed atrial fibrillation: findings from the GLORIA-AF Registry Phase III2025 European Journal of Preventive Cardiology article Medicine Atrial Fibrillation Management and Outcomes Open access
Bernadette Corica, Giulio Francesco Romiti, Marco Proietti, Giuseppe Boriani, Brian Olshansky, Menno Volkert Huisman, +1 more
6citations -
Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial
Natalia Tovar, Valentín Ortiz‐Maldonado, Núria Martínez‐Cibrián, Sergi Betriu, Daniel Esteban, Ana Triguero, +5 more
5citations -
The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer.2023 Journal of Clinical Oncology conference-abstract Medicine Endometrial and Cervical Cancer Treatments
Merve Kaya, Nanda Horeweg, Alexandra F. Leary, Stephen A. Welch, Stefan Kommoss, Nicola Weidner, +13 more
5citations -
Probing the electronic structure and ground state symmetry of gas phase C60+ via VUV photoionization and comparison with theory2024 The Journal of Chemical Physics article Chemistry Fullerene Chemistry and Applications Open access
Helgi Rafn Hróðmarsson, Mathias Rapacioli, Fernand Spiegelman, Gustavo A. García, Jordy Bouwman, Laurent Nahon, +1 more
5citations -
Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
Valentín Ortiz‐Maldonado, Núria Martínez‐Cibrián, Letícia Alserawan, Sergi Betriu, Ana Triguero, Sandra Blum, +8 more
5citations -
S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG
M Lübbert, P. W. Wijermans, Michal Kiciński, Sylvain Chantepie, Walter J. F. M. van der Velden, Richard Noppeney, +26 more
3citations -
Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status
Heiko Becker, Claudia Schmoor, Olga Grishina, Dietmar Pfeifer, Dennis Zimmer, Martina Margrit Crysandt, +27 more
3citations